Retinol-binding protein-4 (RBP-4) along with the lipid profile plays crucial roles in Acute coronary syndrome (ACS). The study aimed to investigate the correlation of RBP-4, lipoprotein combine index (LCI), and RBP-4 + LCI with ACS. 163 ACS and 77 non-CAD in patients were consecutively enrolled in this study. The serum level of RBP-4 was measured via enzyme-linked immunosorbent assay. LCI was calculated using the formula: total cholesterol × triglyceride × low-density lipoprotein cholesterol/high-density lipoprotein cholesterol. RBP-4 ≥4 ng/ml, LCI ≥16 and LCI ≥16 + RBP-4 ≥4 ng/ml were new independent risk factors of ACS, and OR value of LCI ≥16 + RBP-4 ≥4 ng/ml was higher than that of RBP-4 and LCI combined (all p < 0.05). The AUC for LCI + RBP-4 was higher than that for LCI and RBP-4 individually. The risk of high LCI in 1 lesion vessel was greater than those of 2 or ≥3 lesion vessels (all p < 0.05). In 1 lesion vessel or ≥3 lesion vessels group, the risk associated with LCI and RBP-4 combined was higher than the risk of LCI or RBP-4 alone (all p < 0.05). The risk of hypertension, diabetes mellitus, smoking and history of MI increased with numbers of vessels lesion (all p < 0.05). Increase in RBP-4 and LCI values were found to be independent risk factors for ACS, and the risk of the combined rise in LCI and RBP-4 values was higher than LCI or RBP-4 alone. The combined tests of LCI and RBP-4 might be a potential diagnostic marker for ACS.

中文翻译：

---

视黄醇结合蛋白4和脂蛋白结合指数与急性冠状动脉综合征的患病率和诊断的相关性。

视黄醇结合蛋白4（RBP-4）以及脂质分布在急性冠状动脉综合征（ACS）中起着至关重要的作用。该研究旨在探讨RBP-4，脂蛋白结合指数（LCI）和RBP-4 + LCI与ACS的相关性。该研究连续纳入了163例ACS和77例非CAD患者。通过酶联免疫吸附测定法测定RBP-4的血清水平。LCI使用以下公式计算：总胆固醇×甘油三酸酯×低密度脂蛋白胆固醇/高密度脂蛋白胆固醇。RBP-4≥4ng / ml，LCI≥16和LCI≥16+ RBP-4≥4ng / ml是ACS的新的独立危险因素，LCI≥16+ RBP-4≥4ng / ml的OR值是高于RBP-4和LCI的总和（所有p <0.05）。LCI + RBP-4的AUC分别高于LCI和RBP-4的AUC。1个病变血管发生高LCI的风险大于2个或≥3个病变血管的风险（所有p <0.05）。在1个病变血管或≥3个病变血管组中，与LCI和RBP-4联合使用的风险高于单独使用LCI或RBP-4的风险（所有p <0.05）。高血压，糖尿病，吸烟和MI史的风险随着血管病变数目的增加而增加（所有p <0.05）。发现RBP-4和LCI值升高是ACS的独立危险因素，并且LCI和RBP-4值联合升高的风险高于单独的LCI或RBP-4。LCI和RBP-4的组合测试可能是ACS的潜在诊断标记。LCI和RBP-4联合使用的风险高于单独使用LCI或RBP-4的风险（所有p <0.05）。高血压，糖尿病，吸烟和MI史的风险随着血管病变数目的增加而增加（所有p <0.05）。发现RBP-4和LCI值升高是ACS的独立危险因素，并且LCI和RBP-4值联合升高的风险高于单独的LCI或RBP-4。LCI和RBP-4的组合测试可能是ACS的潜在诊断标记。LCI和RBP-4联合使用的风险高于单独使用LCI或RBP-4的风险（所有p <0.05）。高血压，糖尿病，吸烟和MI史的风险随着血管病变数目的增加而增加（所有p <0.05）。发现RBP-4和LCI值升高是ACS的独立危险因素，并且LCI和RBP-4值联合升高的风险高于单独的LCI或RBP-4。LCI和RBP-4的组合测试可能是ACS的潜在诊断标记。